NCT02761694
Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER+, PR+
Other Mutations: AKT, PI3K, PTEN
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Phase 1
Drug Category: Serine-Threonine Kinase Inhibitor

Key Eligibility Criteria:

Gender: All
Age: 18 Years and older (Adult, Senior)
Location of Metastases: 
Additional Notes: Must have AKT 1/2/3 genetic alterations, activating PI3K mutations, PTEN-null, or other known actionable PTEN mutations
Exclusions: 
https://ClinicalTrials.gov/show/NCT02761694